Association of Six Complex Inflammatory Indicators with Prognosis in Patients with Intravenous Thrombolysis Stroke

六项复杂炎症指标与静脉溶栓治疗卒中患者预后的相关性

阅读:2

Abstract

OBJECTIVE: The objective of this study is to examine the correlation between neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), systemic immune inflammation index (SII), systemic inflammation response index (SIRI) and pan-immune-inflammation value (PIV) with the outcome following 3 months of thrombolysis in individuals diagnosed with acute ischemic stroke. METHODS: A retrospective analysis was conducted on a cohort of 762 patients who received intravenous thrombolysis between January 2019 and December 2022. The values of NLR, PLR, LMR, SII, SIRI and PIV were calculated based on relevant blood indices obtained upon admission. Logistic regression analysis using R software was employed to examine the correlation between SIRI, SII, PIV, and poor prognosis following 3 months of thrombolysis, with their distribution analyzed across the study population and various outcomes. Receiver operating characteristic (ROC) curves were utilized to analyze and evaluate their predictive efficacy for adverse outcomes. RESULTS: The unfavorable prognosis group exhibited significant differences from the favorable prognosis group in various hematological markers, including PLR, NLR, LMR, SII, SIRI, and PIV, as indicated by ROC values of 0.613 (95% confidence interval (CI), 0.564-0.661), 0.707 (95% CI, 0.663-0.751), 0.614 (95% CI, 0.567-0.662), 0.715 (95% CI, 672-0.758), 0.631 (95% CI, 0.584-0.679), and 0.569 (95% CI, 0.520-0.619) respectively. (4) Conclusions: PLR, NLR, LMR, SII, SIRI, and PIV demonstrated associations with adverse outcomes at the 3-month mark in patients who underwent intravenous thrombolysis, with NLR (ROC is 0.707) and SII (ROC is 0.715) showing the most pronounced significance and PIV (ROC is 0.569) exhibiting the least significance.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。